756894-33-4Relevant articles and documents
MACROCYCLIC INHIBITORS OF HEPATITIS C PROTEASE
-
Page/Page column 54-55, (2009/10/09)
The invention provides compounds inhibitory to the Hepatitis C viral protease, compositions and combinations including the compounds, methods of treatment of conditions wherein inhibition of the Hepatitis C viral protease is medically indicated, and metho
Synthesis of BILN 2061, an HCV NS3 protease inhibitor with proven antiviral effect in humans
Faucher, Anne-Marie,Bailey, Murray D.,Beaulieu, Pierre L.,Brochu, Christian,Duceppe, Jean-Simon,Ferland, Jean-Marie,Ghiro, Elise,Gorys, Vida,Halmos, Ted,Kawai, Stephen H.,Poirier, Martin,Simoneau, Bruno,Tsantrizos, Youla S.,Llinas-Brunet, Montse
, p. 2901 - 2904 (2007/10/03)
(Equation Presented) The synthesis of BILN 2061, an NS3 protease inhibitor with proven antiviral effect in humans, was accomplished in a convergent manner from four building blocks. The procedure described here was suitable for the preparation of multigra
Macrocyclic peptides active against the hepatitis C virus
-
Page 10, (2010/02/03)
Compounds of formula I: wherein R1 is hydroxy or NHSO2R1A wherein R1A is (C1-8)alkyl, (C3-7)cycloalkyl or {(C1-6)alkyl-(C3-7)cycloalkyl}, which are all optionally substituted from 1 to 3 times with halo, cyano, nitro, O(C1-6)alkyl, amido, amino or phenyl, or R1A is C6 or C10 aryl which is optionally substituted from 1 to 3 times with halo, cyano, nitro, (C1-6)alkyl, O(C1-6)alkyl, amido, amino or phenyl; R2 is (C5-6)cycloalkyl and R3 is cyclopentyl; or a pharmaceutically acceptable salt thereof, useful as inhibitors of the HCV NS3 protease.
